tbuckley/cabot-search huggingface dataset:
Loss of Receptor for Advanced Glycation End Products (RAGE) Defense
Authors: Kara A. Witzke, Aaron I. Vinik, Lisa M. Grant, William P. Grant, Henri K. Parson, Gary L. Pittenger, Niculina Burcus
Journal: Diabetes Care (2011)

OBJECTIVE This study investigated the relationship between circulating soluble receptor for advanced glycation end products (sRAGE) and parameters of bone health in patients with Charcot neuroarthropathy (CNA).

RESEARCH DESIGN AND METHODS Eighty men (aged 55.3 ± 9.0 years), including 30 healthy control subjects, 30 type 2 diabetic patients without Charcot, and 20 type 2 diabetic patients with stage 2 (nonacute) CNA, underwent evaluations of peripheral and autonomic neuropathy, nerve conduction, markers of bone turnover, bone mineral density, and bone stiffness of the calcaneus.

RESULTS CNA patients had worse peripheral and autonomic neuropathy and lower bone stiffness index than the diabetic or control individuals (77.1, 103.3, and 105.1, respectively; P   0.05). CNA subjects also had lower sRAGE levels than control (162 vs. 1,140 pg/mL; P < 0.01) and diabetic (162 vs. 522 pg/mL; P < 0.05) subjects, and higher circulating osteocalcin levels.

CONCLUSIONS CNA patients had significantly lower circulating sRAGE, with an accompanying increase in serum markers of bone turnover, and reduced bone stiffness in the calcaneus not accompanied by reductions in bone mineral density. These data suggest a failure of RAGE defense mechanisms against oxidative stress in diabetes. Future studies should determine if medications that increase sRAGE activity could be useful in mitigating progression to CNA.
Primed-GCSF BMT Following Reduced Intensity Conditioning Regimen (RIC) for Patients (pts) with Poor-Prognosis, Heavily Pre-Treated, Hodgkin's Disease (HD).
Authors: Rodolfo Calixto, Mauricio Ostronoff, Fabiana Ostronoff, Djenane Manso, ANA Patricia Souto Maior, Alexandre Sucupira, Rodrigo Florencio, Monique Martins, Luis Fabio Botelho, Mariana Coutinho
Journal: Blood (2010)
High Rates of Severe aGVHD with Tacrolimus and Mycophenolate Mofetil in a Large Cohort of Related and Unrelated Allogeneic Transplant Patients
Authors: Zaid Al-Kadhimi, Zartash Gul, Wei Chen, Daryn Smith, Abhinav Deol, Muneer H. Abidi, Lois Ayash, Lawrence G Lum, Voravit Ratanatharathorn, Joseph P. Uberti
Journal: Blood (2012)
An exploratory study using framework analysis to investigate health‐seeking behaviour in patients with psoriasis
Authors: J.K. Simpson, M. Wilson, A.A. Ahmed, A. Mizara, A. Clarke, S.R. McBride
Journal: British Journal of Dermatology (2017)

Psoriasis is a long-term inflammatory skin disorder, with negative effects on employment, relationships and social function, frequently causing reduced quality of life. People with psoriasis often present to secondary care late into their condition but the reasons for this are unknown.To examine the patient pathway, health-seeking behaviour and drivers for referral to secondary care in patients with psoriasis.Sixteen patients with mild-to-severe psoriasis, newly referred to secondary care participated in a semi-structured interview. Scripts were analysed by a thematic framework.The median duration of time living with psoriasis was 15 years at referral. Drivers of secondary care referral included rapid deterioration or extremis, development of comorbidities, knowledge of treatment options, and influence of partners and friends. Reasons for late presentation to secondary care include familial experience of psoriasis, lack of follow-up after the initiation of treatments, beliefs that psoriasis is incurable and must be tolerated, and that psoriasis is not life threatening and therefore not worthy of medical help and difficulty in obtaining a secondary care referral. A common pathway from seeking help at psoriasis onset, evolving into the development of delayed health seeking later in the pathway, was identified.Identifying the causes of delay in presentation to secondary care and effective treatment ascertains key areas to target. Health seeking early in the disease pathway provides a 'window of opportunity' for intervention, which may enable people with psoriasis to obtain early, effective treatment and achieve their full life potential.
Corrigendum re: “Impact of Prostate-specific Antigen (PSA) Screening Trials and Revised PSA Screening Guidelines on Rates of Prostate Biopsy and Postbiopsy Complications” [Eur Urol 2017;71:55–65]
Authors: Boris Gershman, Holly K. Van Houten, Jeph Herrin, Daniel M. Moreira, Simon P. Kim, Nilay D. Shah, R. Jeffrey Karnes
Journal: European Urology (2017)
Low Dose Bexarotene and Ultraviolet A Photochemotherapy (PUVA) In a Prospective Phase II Clinical Study for Refractory and/or Resistant Cutaneous T Cell Lymphomas (CTCL)
Authors: Serena Rupoli, Nicola Pimpinelli, Gaia Goteri, Lucia Canafoglia, Paola Picardi, Giuliano Brandozzi, Stefano Pulini, Irene Federici, Anna Rita Scortechini, Simona Tomassetti, Lisa Albani, Lidia Da Lio, Mirella Giangiacomi, Pietro Leoni
Journal: Blood (2010)
The Novel De-Immunized Anti-CD20-IL-2 Immunocytokine DI-Leu16-IL-2 Is Effective in SCID Mice Bearing Rituximab-Resistant Human Lymphoma Xenografts.
Authors: Jan O. Staak, David Colcher, Scott Lauder, Jianyi Wang, Stephen D. Gillies, Andrew A. Raubitschek
Journal: Blood (2004)
CD8-Depleted Donor Lymphocyte Infusions Can Boost Immune Reconstitution after Haploidentical Stem Cell Transplantation Following Reduced-Intensity Conditioning Regimen.
Authors: Paolo Corradini, Anna Raganato, Cristiana Carniti, Matteo Carrabba, Farina Lucia, Vittorio Montefusco, Raffaella Milani, Marco Milanesi, Paolo Longoni, Elisabetta Zorzan, Lorenza Gandola, Claudia Lombardo, Anna Dodero
Journal: Blood (2006)
Bcl-2 Inhibitor ABT-263 Targets Oxidative Phosphorylation and Selectively Eradicates Quiescent Human Leukemia Stem Cells
Authors: Eleni D Lagadinou, Alexander Sach, Kevin P Callahan, Randall M. Rossi, Sarah Neering, Shanshan Pei, Kristen O'Dwyer, Jane L. Liesveld, Paul S. Brookes, Michael W. Becker, Craig T. Jordan
Journal: Blood (2012)
Polymorphisms of Exon 10 in Stem Cell Factor Receptor KIT Are Associated with a Significantly Improved Relapse-Free Survival in Childhood AML.
Authors: Muriel Malaise, Juan Du, Beate Junk, Kerstin Wittke, Martin Zimmermann, Dirk Reinhardt, Konstanze Doehner, Klaus-Michael Debatin, Selim Corbacioglu
Journal: Blood (2009)
Microarray Gene Expression Signature Indicates ARSD As a New Marker Associated with Igvh Mutational Status, ZAP-70 and Disease Progression in CLL,
Authors: Alessandra Trojani, Barbara Di Camillo, Alessandra Tedeschi, Lodola Milena, Simona Montesano, Francesca Ricci, Eleonora Vismara, Antonino Greco, Silvio Veronese, Anna Colosimo, Barbara Scarpati, Aldo Orlacchio, Sabata Martino, Chiara Colombo, Maria Angela Mura, Michele Nichelatti, Marco Montillo, Enrica Morra
Journal: Blood (2011)
Circulating Exosomal MicroRNA-21 As a Potential Biomarker That May Predict Response to Azacitidine Treatment in Myelodysplastic Syndromes,
Authors: Yoo-Hong Min, Sulhee Yoon, Doh Yu Hwang, Yundeok Kim, Yeo-Kyeoung Kim, Yuri Kim, Jae Yong Cho, Jin Seok Kim, Soo Jeong Kim, June-Won Cheong, Hyeoung Joon Kim
Journal: Blood (2011)
Red Cell Band 3 Content Evaluation By Eosin Maleimide (EMA) Fluorescence: Beyond Diagnosis of Dominant Hereditary Spherocytosis (HS)
Authors: Ahmar Urooj Zaidi, Miguel Herrera-Martinez, Gerard W. Goyette, Steven Buck, Manisha Gadgeel, Arathi Mohan, Bulent Ozgonenel, Michael U Callaghan, Robert M. Johnson, Yaddanapudi Ravindranath
Journal: Blood (2015)
Clofarabine Produces Durable Remissions in Older Patients with AML with Unfavorable Prognostic Factors and Multiple Comorbidities.
Authors: Stefan Faderl, Harry P Erba, David F. Claxton, M. Arellano, Roger M Lyons, Tibor J. Kovacsovics, Janice Gabrilove, Elizabeth Anderson, Elly Barry, Hagop M. Kantarjian
Journal: Blood (2009)
Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial
Authors: Preetesh Jain, Michael Keating, Sarah Renner, Charles Cleeland, Huang Xuelin, Graciela Nogueras Gonzalez, David Harris, Ping Li, Zhiming Liu, Ivo Veletic, Uri Rozovski, Nitin Jain, Phillip Thompson, Prithviraj Bose, Courtney DiNardo, Alessandra Ferrajoli, Susan O'Brien, Jan Burger, William Wierda, Srdan Verstovsek, Hagop Kantarjian, Zeev Estrov
Journal: The Lancet Haematology (2017)
Weekly cisplatin-epirubicin-paclitaxel (PET) vs. triweekly epirubicin-paclitaxel (ET) in metastatic breast cancer (MBC). Interim analysis of the SICOG 9908 phase III trial
Authors: L. Maiorino, G. Frasci, None D'Aiuto, P. Comella, R. Thomas, None D'Aniello, P. Silvestro, A. Russo, L. Lapenta, G. Comella
Journal: Journal of Clinical Oncology (2004)

640 Background: The present study aimed at evaluating whether the PET weekly regimen could produce a significant prolongation of TTF in MBC patients in comparison with standard 3-weekly epirubicin-taxol administration. Patients and Methods: Previously untreated metastatic BC pts, aging ≤ 70 years, and with ECOG P.S. ≤ 2 were eligible. Women were randomised to receive 12 weekly PET (cisplatin 30 mg/m2/week + epirubicin 50 gm/m2/week + paclitaxel 120 mg/m2/week + G-CSF) cycles or 6 triweekly ET (epirubicin 90 mg/m2/ + paclitaxel 175 mg/m2 ) cycles. The Time to Treatment Failure was considered the main end point. An accrual of 120 patients per arm was planned, with an interim analysis on the first 60 evaluable patients of each arm, according to the Shaid's design. Results: As of December the 1st 2003, overall 132 patients have been recruited (PET=64; ET=68). 120 patients are evaluable for clinical response, the remaining 12 patients being too early (10) or not evaluable (2) since they were lost to follow-up. 11 Complete (20%) and 34 partial (60%) responses were recorded in the PET arm, giving a 80% ORR. 8 Complete (12%) and 24 partial (38%) responses were registered in the ET arm, for a 50% ORR; (p=0.0004) At a median follow-up of 21 (range:1–48) months, 78 failures have occurred (PET=38; ET=40), median TTF being 13.2 months and 14 months in PET and ET arm, respectively (p=0.97). Only 43 deaths occurred (PET 18, ET 25), 4-year survival probability being: PET= 44 %; ET= 39 %. Anaemia, mucositis, peripheral neuropathy, and gastrointestinal toxicity were substantially more frequent in the PET arm. Conclusions: According to these preliminary data, the PET weekly regimen can significantly increase the probability of achieving a major response in patients with metastatic breast cancer when compared with a standard triweekly ET regimen. However, both the Clinical Complete Response rate and Time to Treatment Failure are not significantly different in the two arms; moreover, anemia and nonhematological toxicity were sometimes relevant in the PET arm. The accrual still proceeds until the planned sample size No significant financial relationships to disclose.
Risk Factors to Develop Sclerotic Chronic GvHD After Allogeneic HSCT: Preliminary Results of a Multicentre Retrospective study From the Société Française De Greffe De Moelle Et De Thérapie Cellulaire (SFGM-TC)
Authors: Marie Y. Detrait, Roberto Crocchiolo, Stephane Vigouroux, Jacques-Olivier Bay, Mohamad Sobh, Fiorenza Barraco, Stéphane Morisset, Reza Tabrizi, Nicole Raus, Regis Peffault de la Tour, Gérard Socié, Ibrahim Yakoub-Agha, Mohamad Mohty, Noel Milpied, Didier Blaise, Mauricette Michallet
Journal: Blood (2012)
Is Differential Activity of Enoxaparin and Unfractionated Heparin According to the Location of Deep-Vein Thrombosis in Acute Ischemic Stroke Patients Driven by Different Pathogenic Mechanisms?.
Authors: Ludovic Drouet, David G. Sherman, Gregory W. Albers, Christopher Bladin, Cesare Fieschi, Alberto A. Gabbai, Carlos S. Kase, William O’Riordan, Graham F. Pineo
Journal: Blood (2007)
Combined Action of Endothelial and Mesenchymal Niche Cells to Amplify Hematopoietic Progenitor Expansion in a Humanized System
Authors: Margareta Frühwirth, Daniela Thaler, Andreas Reinisch, Katharina Schallmoser, Eva Rohde, Nicole A Hofmann, Werner Linkesch, Dirk Strunk
Journal: Blood (2008)
Correction: Preventing tumor escape by targeting a post-proteasomal trimming independent epitope
Authors: Ana Textor, Karin Schmidt, Peter-M. Kloetzel, Bianca Weißbrich, Cynthia Perez, Jehad Charo, Kathleen Anders, John Sidney, Alessandro Sette, Ton N.M. Schumacher, Christin Keller, Dirk H. Busch, Ulrike Seifert, Thomas Blankenstein
Journal: The Journal of Experimental Medicine (2017)

Vol. 213, No. 11, October 2016. Pages [2333–2348][1].

The authors regret that in Fig. 1 of their original article, part of the Vb9 sequence from MP71-TCR-IV–containing CDR3 and Jb2.5 regions was listed incorrectly. The corrected figure appears below. The online HTML and PDF versions of this
Targeting Histone Deacetylases and Unfolded Protein Mediated Endoplasmic Reticulum (ER) Stress as a Strategy Against Human Mantle Cell Lymphoma.
Authors: Rekha Rao, Warren Fiskus, Rajeshree Joshi, Jianguang Chen, Pravina Fernandez, Yongchao Wang, Pearl Lee, Anand Jillella, Jianguo Tao, Peter Atadja, Eduardo Sotomayor, Kapil Bhalla
Journal: Blood (2007)
Chromosomal Abnormalities and TET2 Involvement in Therapy-Related Myelodysplastic Syndromes (t-MDS) and Acute Myeloid Leukemias (t-AML).
Authors: Paolo Bernasconi, Irene Dambruoso, Marina Boni, Cesare Astori, Paola Maria Cavigliano, Patrizia Zappasodi, Ilaria Giardini, Barbara Rocca, Rita Zappatore, Celeste Calvello, Marilena Caresana, Ercole Brusamolino, Carlo Castagnola, Mario Lazzarino
Journal: Blood (2009)
Direct Coregulation of Notch1 By Zmiz1 in T-Cell Development and Leukemia
Authors: Nancy Pinnell, Ran Yan, Hyoje Cho, Paula Jeon, Theresa Keeley, Jordan McHugh, Yiran Liu, Kojo S.J. Elenitoba-Johnson, Ivan Maillard, Linda C. Samuelson, Tomasz Cierpicki, Mark Y. Chiang
Journal: Blood (2014)
Reversibility of Renal Failure in Newly Diagnosed Patients with Multiple Myeloma Treated with High-Dose Dexamethasone Containing Regimens and the Impact of Novel Agents.
Authors: Efstathios Kastritis, Athanasios Anagnostopoulos, Aristotle Bamias, Maria Roussou, Dimitra Gika, Vassiliki Koutsoukou, Charis Matsouka, Despina Barmparousi, Meletios A. Dimopoulos
Journal: Blood (2006)
Identification of Molecular Risk Score in Advanced Hodgkin Lymphoma: Integrating Tumor and Microenvironment Signatures.
Authors: Beatriz Sánchez-Espiridión, Carlos Montalbán, Mónica García-Cosio, Jose García-Laraña, Javier Menarguez, Pilar Sabin, Rafael Ramos, José Rodríguez, Francisco Mestre, Miguel Canales, Francisco Javier Alves, Araceli Canovas, Carmen Camarero, Antonio Salar, Sergi Serrano, Angel Castaño, Pedro Sánchez-Godoy, Águeda Bas, Reyes Arranz, Agustín Acevedo, Concepción Rayón, Manuel F. Fresno, Carlos Santonja, Jose Luis López, Manuela Mollejo, Miguel A. Cruz, Hugo Álvarez-Arguelles, Marta LLanos, Carmen Martín, Rafael Martínez, Joaquín González-Carrero, Concepción Poderos, Francisco Mazorra, Eulogio Conde, Teresa Flores, Ramón García-Sanz, Jerónimo Forteza, Máximo Fraga, Jose Luis Bello, María Jose Mestre, Miguel Méndez, Rubén Quibén, Luz Borbolla, Ana Marin-Niebla, Eduardo Ríos, Manuel M. Morente, Miguel A. Piris, Juan F. García
Journal: Blood (2009)
Epigenetic Changes in CEBPα Gene and Xenotransplantation Model of B Cell Precursor Acute Lymphoblastic Leukemia Switching to Monocytoid Lineage During the Early Phase of the Treatment
Authors: Lucie Slamova, Julia Starkova, Beat C Bornhauser, Eva Fronkova, Marketa Kubricanova Zaliova, Leona Reznickova, Jana Volejnikova, Elena Vodickova, Frederik W Van Delft, Zuzana Zemanova, Gunnar Cario, Tomas Kalina, Karel Fiser, Maria E. Figueroa, Michael Dworzak, Jan Zuna, Jan Trka, Jan Stary, Ondrej Hrusak, Jean-Pierre Bourquin, Ester Mejstrikova
Journal: Blood (2012)
Emergency admissions for diabetes increase more quickly in deprived areas of England
Authors: Susan Mayor
Journal: BMJ (2017)

Deaths due to diabetes have decreased but emergency hospital admissions related to the condition have increased more quickly in deprived areas of England than in wealthier regions in recent years, show the results of a longitudinal study assessing the impact of NHS efforts to reduce inequalities in diabetes outcomes.1

Type 2 diabetes is about 50% more prevalent in the fifth of people with the greatest levels of deprivation than in the least deprived. Several UK initiatives over the past decade have provided targeted support for primary care interventions for chronic conditions, including diabetes, in disadvantaged adults.

Researchers analysed …
A Phase II Trial of R-CHOP Followed by Zevalin Radioimmunotherapy for Patients with Previously Untreated Stages I and II CD20+ Diffuse Large Cell Non-Hodgkin's Lymphoma: an Eastern Cooperative Oncology Group Study (E3402).
Authors: Thomas E. Witzig, Fangxin Hong, Ivana N. Micallef, Randy D. Gascoyne, Ahmet Dogan, Henry Wagner, Ranjana H. Advani, Brad S. Kahl, Sandra J. Horning
Journal: Blood (2012)
A Lymphoid Progenitor Propagates AML in a Mouse Model of CALM/AF10 Positive Leukemia.
Authors: Aniruddha Deshpande, Monica Cusan, Viajy P.S. Rawat, Hendrik Reuter, Leticia Quintanilla-Martinez, Alexandre Krause, Wolfgang Hiddemann, Peter Lichter, Stefan K. Bohlander, R. Keith Humphries, Michaela Feuring-Buske, Christian Buske
Journal: Blood (2005)
Clinical features of amyopathic dermatomyositis
Authors: Zhou Xiaojie, Yuan Shuanglong, Zhou Lei, Gong Lu
Journal: BMJ (2010)

The clinical features of 8 cases with amyopathic dermatomyositis (ADM) wereretrospectively compared with those of 53 cases with typical dermatomyositis ( DM). Incidence of interstitiallung disease, joint pain, fever, concurrent cancer were 4/8, 3/8, 3/8 and 0 in ADM group and those were 40% , 34% , 32% and 11 % in DM group respectively. The prevalence of interstitial lung disease in ADMgroup was significantly higher than that in DM group, which indicates that ADM patient should be properlytreated.

Key words: 
Dermatomyositis;  Pneumonia, Interstitial
Mitochondrial redox plays a critical role in the paradoxical effects of NAPDH oxidase-derived ROS on coronary endothelium
Authors: Ehtesham Shafique, Anali Torina, Karla Reichert, Bonnie Colantuono, Nasifa Nur, Khawaja Zeeshan, Vani Ravichandran, Yuhong Liu, Jun Feng, Khawaja Zeeshan, Laura E. Benjamin, Kaikobad Irani, Elizabeth O. Harrington, Frank W. Sellke, Md. Ruhul Abid
Journal: Cardiovascular Research (2016)

There are conflicting reports on the role of reactive oxygen species (ROS) i.e. beneficial vs. harmful, in vascular endothelium. Here, we aim to examine whether duration of exposure to ROS and/or subcellular ROS levels are responsible for the apparently paradoxical effects of oxidants on endothelium. We have recently generated binary (Tet-ON/OFF) conditional transgenic mice (Tet-Nox2:VE-Cad-tTA) that can induce 1.8 ± 0.42-fold increase in NADPH oxidase (NOX)-derived ROS specifically in vascular endothelium upon withdrawal of tetracycline from the drinking water. Animals were divided in two groups: one exposed to high endogenous ROS levels for 8 weeks (short-term) and the other for 20 weeks (long-term). Using endothelial cells (EC) isolated from mouse hearts (MHEC), we demonstrate that both short-term and long-term increase in NOX-ROS induced AMPK-mediated activation of eNOS. Interestingly, although endothelium-dependent nitric oxide (NO)-mediated coronary vasodilation was significantly increased after short-term increase in NOX-ROS, coronary vasodilation was drastically reduced after long-term increase in ROS. We also show that short-term ROS increase induced proliferation in EC and angiogenic sprouting in the aorta. In contrast, long-term increase in cytosolic ROS resulted in nitrotyrosine-mediated inactivation of mitochondrial (mito) antioxidant MnSOD, increase in mito-ROS, loss of mitochondrial membrane potential (Δψm), decreased EC proliferation and angiogenesis. The findings suggest that NOX-derived ROS results in increased mito-ROS. Whereas short-term increase in mito-ROS was counteracted by MnSOD, long-term increase in ROS resulted in nitrotyrosine-mediated inactivation of MnSOD, leading to unchecked increase in mito-ROS and loss of Δψm followed by inhibition of endothelial function and proliferation.
Abstract 18995: The Influence of Osteoglycin on Remodelling Processes After Myocardial Infarction
Authors: Sandra Voss, Holger M Nef, Susanne Braendlin, Christian Troidl, Sawa Kostin, Sebastian Szardien, Astrid Wietelmann, Albrecht Elsasser, Christian W Hamm, Helge Mollmann
Journal: Circulation (2010)

Background: After myocardial infarction, inflammatory processes as well as matrix metalloproteinases (MMP) and their inhibitors play a pivotal role in the formation of a resilient scar tissue. The ...
Expression of Factors in the Hepatocyte Growth Factor (HGF) Pathway in Whole Bone Marrow Biopsies in Association to the Osteolytic Bone Disease of Multiple Myeloma
Authors: Ida Bruun Kristensen, Jacob Haaber, Maria B Lyng, Lise Pedersen, Lars Melholt Rasmussen, Henrik J Ditzel, Niels Abildgaard
Journal: Blood (2012)
CD8+ but Not CD4+ T Cells Require Cognate Interactions with Target Tissues To Mediate GVHD across Only Minor H Antigens but CD4+ and CD8+ T Cells Both Require Direct Leukemic Contact for GVL.
Authors: Warren D. Shlomchik, Catherine Matte, Jinli Liu, Dhanpat Jain, Jennifer McNiff
Journal: Blood (2005)
Phamacokinetics (PK) Substudy of Rituximab in a Prospective Clinical Trial for Pediatric Chronic Immune Thrombocytopenic Purpura (cITP).
Authors: Carolyn M. Bennett, James B. Bussel, Brigitta U. Mueller, Thomas C. Abshire, Hadi Sawaf, Theodore B. Moore, Mignon L. Loh, Zora R. Rogers, Henry A. Feldman, Ellis J. Neufeld
Journal: Blood (2005)
MicroRNA expression patterns and signalling pathways in the development and progression of childhood solid tumours
Authors: Anna L. Leichter, Michael J. Sullivan, Michael R. Eccles, Aniruddha Chatterjee
Journal: Molecular Cancer (2017)

The development of childhood solid tumours is tied to early developmental processes. These tumours may be complex and heterogeneous, and elucidating the aberrant mechanisms that alter the early embryonic environment and lead to disease is essential to our understanding of how these tumours function. MicroRNAs (miRNAs) are vital regulators of gene expression at all stages of development, and their crosstalk via developmental signalling pathways is essential for orchestrating regulatory control in processes such as proliferation, differentiation and apoptosis of cells. Oncogenesis, from aberrant miRNA expression, can occur through amplification and overexpression of oncogenic miRNAs (oncomiRs), genetic loss of tumour suppressor miRNAs, and global miRNA reduction from genetic and epigenetic alterations in the components regulating miRNA biogenesis. While few driver mutations have been identified in many of these types of tumours, abnormal miRNA expression has been found in a number of childhood solid tumours compared to normal tissue. An exploration of the network of key developmental pathways and interacting miRNAs may provide insight into the development of childhood solid malignancies and how key regulators are affected. Here we present a comprehensive introduction to the roles and implications of miRNAs in normal early development and childhood solid tumours, highlighting several tumours in depth, including embryonal brain tumours, neuroblastoma, osteosarcoma, Wilms tumour, and hepatoblastoma. In light of recent literature describing newer classifications and subtyping of tumours based on miRNA profiling, we discuss commonly identified miRNAs, clusters or families associated with several solid tumours and future directions for improving therapeutic approaches.
Prognostic Impact of Pretransplantation Minimal Residual Disease Detection for Flow Cytometric, on Outcome of Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia. a Single Center Experience in Colombia over 14 Years
Authors: Andres Armando Borda Molina, Iris Cordoba, Virginia Abello, Carmen Rosales, Rosales Manuel, Javier Figueroa, Adriana Villegas, Monica Osuna, Enrique Pedraza
Journal: Blood (2015)